Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53.

Vidimar V, Licona C, Cerón-Camacho R, Guerin E, Coliat P, Venkatasamy A, Ali M, Guenot D, Le Lagadec R, Jung AC, Freund JN, Pfeffer M, Mellitzer G, Sava G, Gaiddon C.

Cancer Lett. 2019 Jan;440-441:145-155. doi: 10.1016/j.canlet.2018.09.029. Epub 2018 Oct 17.

PMID:
30339780
2.

Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review.

Grisafi D, Ceschi A, Sava G, Avalos Clerici V, Scaglione F.

Eur J Clin Pharmacol. 2018 Dec;74(12):1663-1670. doi: 10.1007/s00228-018-2511-8. Epub 2018 Jul 14. No abstract available.

PMID:
30008120
3.

Chemical and Molecular Approach to Tumor Metastases.

Bergamo A, Sava G.

Int J Mol Sci. 2018 Mar 14;19(3). pii: E843. doi: 10.3390/ijms19030843.

4.

The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects.

Lee RFS, Escrig S, Maclachlan C, Knott GW, Meibom A, Sava G, Dyson PJ.

Int J Mol Sci. 2017 Aug 29;18(9). pii: E1869. doi: 10.3390/ijms18091869.

5.

Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.

Bergamo A, Pelillo C, Chambery A, Sava G.

J Inorg Biochem. 2017 Mar;168:90-97. doi: 10.1016/j.jinorgbio.2016.11.031. Epub 2016 Dec 2.

PMID:
28064102
6.

Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties.

Castellarin A, Zorzet S, Bergamo A, Sava G.

Int J Mol Sci. 2016 Aug 2;17(8). pii: E1254. doi: 10.3390/ijms17081254.

7.

Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.

Pelillo C, Mollica H, Eble JA, Grosche J, Herzog L, Codan B, Sava G, Bergamo A.

J Inorg Biochem. 2016 Jul;160:225-35. doi: 10.1016/j.jinorgbio.2016.02.025. Epub 2016 Feb 27.

PMID:
26961176
8.

RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.

Bergamo A, Gerdol M, Lucafò M, Pelillo C, Battaglia M, Pallavicini A, Sava G.

Metallomics. 2015 Oct;7(10):1439-50. doi: 10.1039/c5mt00081e. Epub 2015 Sep 4.

PMID:
26338673
9.

Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis.

Gerdol M, Puillandre N, De Moro G, Guarnaccia C, Lucafò M, Benincasa M, Zlatev V, Manfrin C, Torboli V, Giulianini PG, Sava G, Venier P, Pallavicini A.

Genome Biol Evol. 2015 Jul 21;7(8):2203-19. doi: 10.1093/gbe/evv133.

10.

Effects of Two Fullerene Derivatives on Monocytes and Macrophages.

Pacor S, Grillo A, Đorđević L, Zorzet S, Lucafò M, Da Ros T, Prato M, Sava G.

Biomed Res Int. 2015;2015:915130. doi: 10.1155/2015/915130. Epub 2015 May 19.

11.

Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin.

Pelillo C, Bergamo A, Mollica H, Bestagno M, Sava G.

J Cell Biochem. 2015 Oct;116(10):2385-96. doi: 10.1002/jcb.25189.

PMID:
25857463
12.

Linking the future of anticancer metal-complexes to the therapy of tumour metastases.

Bergamo A, Sava G.

Chem Soc Rev. 2015 Dec 21;44(24):8818-35. doi: 10.1039/c5cs00134j. Epub 2015 Mar 26. Review.

PMID:
25812154
13.

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Leijen S, Burgers SA, Baas P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH.

Invest New Drugs. 2015 Feb;33(1):201-14. doi: 10.1007/s10637-014-0179-1. Epub 2014 Oct 25.

PMID:
25344453
14.

Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.

Bergamo A, Riedel T, Dyson PJ, Sava G.

Invest New Drugs. 2015 Feb;33(1):53-63. doi: 10.1007/s10637-014-0175-5. Epub 2014 Oct 23.

PMID:
25338748
15.

Modulation of activity of known cytotoxic ruthenium(III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo.

Hudej R, Miklavcic D, Cemazar M, Todorovic V, Sersa G, Bergamo A, Sava G, Martincic A, Scancar J, Keppler BK, Turel I.

J Membr Biol. 2014 Dec;247(12):1239-51. doi: 10.1007/s00232-014-9696-2. Epub 2014 Jun 24.

PMID:
24957014
16.

Human recombinant lysozyme downregulates advanced glycation endproduct-induced interleukin-6 production and release in an in-vitro model of human proximal tubular epithelial cells.

Gallo D, Cocchietto M, Masat E, Agostinis C, Harei E, Veronesi P, Sava G.

Exp Biol Med (Maywood). 2014 Mar;239(3):337-46. doi: 10.1177/1535370213518281. Epub 2014 Feb 4.

PMID:
24495950
17.

Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq.

Lucafò M, Gerdol M, Pallavicini A, Pacor S, Zorzet S, Da Ros T, Prato M, Sava G.

Toxicology. 2013 Dec 6;314(1):183-92. doi: 10.1016/j.tox.2013.10.001. Epub 2013 Oct 12.

PMID:
24125657
18.

Microencapsulation of bioactive principles with an airless spray-gun suitable for processing high viscous solutions.

Cocchietto M, Blasi P, Lapasin R, Moro C, Gallo D, Sava G.

J Funct Biomater. 2013 Nov 19;4(4):312-28. doi: 10.3390/jfb4040312.

19.

Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.

Vadori M, Pacor S, Vita F, Zorzet S, Cocchietto M, Sava G.

J Inorg Biochem. 2013 Jan;118:21-7. doi: 10.1016/j.jinorgbio.2012.09.018. Epub 2012 Sep 26.

PMID:
23123335
20.

Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity.

Vidimar V, Meng X, Klajner M, Licona C, Fetzer L, Harlepp S, Hébraud P, Sidhoum M, Sirlin C, Loeffler JP, Mellitzer G, Sava G, Pfeffer M, Gaiddon C.

Biochem Pharmacol. 2012 Dec 1;84(11):1428-36. doi: 10.1016/j.bcp.2012.08.022. Epub 2012 Sep 1.

PMID:
22964219

Supplemental Content

Loading ...
Support Center